Earlier quoted context omitted.
Yes, the fraud product from a one-product-wonder public company Amarin (NASDAQ: AMRN). (see my comment below).
"fraud product" - Do you mean the product that has been FDA approved for 6 years? Is the FDA "in" on the fraud? Is the New England Journal of Medicine in too? Does having one product (that sold $xxx mil last year) make a bad company? Or one that put all of it's chips into this long term outcomes study? (which has now paid off) Why do you care so strongly about this?
A way to scam money out of Medicare.
Using mineral oil in the study to make their product look superior.
I'm not the only one to share those concerns: https://www.forbes.com/sites/matthewherper/2018/11/10/fish-o...
The biomarkers of patients in the PLACEBO group decreased significantly (up to 30%). Why?
"But what seriously bothered five of the six cardiologists I spoke to was that the mineral oil had not behaved as a placebo at all. In other studies of cardiovascular drugs, blood test results on placebo do not budge. That’s not what happened here. Patients who received mineral oil saw their levels of low-density lipoprotein, the bad cholesterol, increase 10% to 84 milligrams per deciliter, 6% more than in the Vascepa group, according to the New England Journal of Medicine paper. What’s more, other blood test results used by cardiologists also went in the wrong direction. These changes were included in a supplement to the scientific paper, but not in the study itself. Levels of c-reactive protein, a measure of inflammation that is used to help calculate heart risk by some doctors, increased from 2.1 milligrams per liter to 2.8 milligrams per liter, a 30% increase. Could the placebo be causing some heart problems or strokes, making Vascepa look better than it really is?"
Shame on NPR for the sloppy reporting.